Overview
- Hologic’s board unanimously approved the transaction, and the company will be delisted from Nasdaq after closing while retaining its name and Marlborough, Massachusetts headquarters.
- Shareholders will receive up to $79 per share, comprising $76 in cash at closing plus as much as $3 contingent on future breast health revenue targets for fiscal 2026 and 2027.
- The enterprise value of roughly $18.3 billion reflects Hologic’s approximately $2.2 billion in cash and short-term investments and about $2.5 billion in debt.
- The deal remains subject to shareholder and regulatory reviews, with completion expected in the first half of next year.
- Hologic shares rose nearly 4% to about $74.62 after the announcement, and the sponsors plan significant minority investments from an ADIA unit and a GIC affiliate.